Search Results - "Dʼhaens, Geert R"

Effects of infliximab retreatment after consecutive discontinuation of infliximab and adalimumab in refractory Crohn's disease by Brandse, Johannan F, Peters, Charlotte P, Gecse, Krisztina B, Eshuis, Emma J, Jansen, Jeroen M, Tuynman, Hans A, Löwenberg, Mark, Ponsioen, Cyriel Y, van den Brink, Gijs R, DʼHaens, Geert R

“…Switches between anti-tumor necrosis factor agents in the treatment of Crohn's disease (CD) occur in case of treatment failure, intolerance, or patient…”
Get full text

A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease by Brandse, Johannan F, Mould, Diane, Smeekes, Oscar, Ashruf, Yaël, Kuin, Sabine, Strik, Anne, van den Brink, Gijs R, DʼHaens, Geert R

“…Several factors influencing the pharmacokinetics of infliximab (IFX) in inflammatory bowel disease (IBD) have been identified. We studied the impact of…”
Get full text

Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy by De Vos, Martine, Louis, Edouard J, Jahnsen, Jørgen, Vandervoort, Jo G P, Noman, Maja, Dewit, Olivier, Dʼhaens, Geert R, Franchimont, Denis, Baert, Filip J, Torp, Roald A, Henriksen, Magne, Potvin, Philippe M R, Van Hootegem, Philippe P, Hindryckx, Pieter M, Moreels, Tom G, Collard, Arnaud, Karlsen, Lars Normann, Kittang, Eirik, Lambrecht, Guy, Grimstad, Tore, Koch, Jonas, Lygren, Idar, Coche, Jean-Claude R J, Mana, Fazia, Van Gossum, André, Belaiche, Jacques, Cool, Mike R, Fontaine, Fernand, Maisin, Jean-Marc G, Muls, Vinciane, Neuville, Bart, Staessen, Dirk A J, Van Assche, Gert A, de Lange, Thomas, Solberg, Inger Camilla, Vander Cruyssen, Bert J K, Vermeire, Severine A R A

“…This study examined whether fecal calprotectin can be used in daily practice as a marker to monitor patients with ulcerative colitis (UC) receiving infliximab…”
Get full text

A systematic review of the measurement of endoscopic healing in ulcerative colitis clinical trials: recommendations and implications for future research by Samaan, Mark A, Mosli, Mahmoud H, Sandborn, William J, Feagan, Brian G, DʼHaens, Geert R, Dubcenco, Elena, Baker, Kenneth A, Levesque, Barrett G

“…Assessment of endoscopic disease activity, as measured by various endoscopic evaluative instruments, is an essential part of quantifying disease activity in…”
Get full text

Presenteeism in Inflammatory Bowel Diseases: A Hidden Problem with Significant Economic Impact by Zand, Aria, van Deen, Welmoed K, Inserra, Elizabeth K, Hall, Laurin, Kane, Ellen, Centeno, Adriana, Choi, Jennifer M, Ha, Christina Y, Esrailian, Eric, DʼHaens, Geert R, Hommes, Daniel W

“…Indirect costs associated with impaired productivity at work (presenteeism) due to inflammatory bowel disease (IBD) are a major contributor to health…”
Get full text

Incidence and Severity of Prepouch Ileitis: A Distinct Disease Entity or a Manifestation of Refractory Pouchitis? by Samaan, Mark A, de Jong, Djuna, Sahami, Saloomeh, Morgan, Samantha, Fragkos, Konstantinos, Subramaniam, Sharmila, Kok, Klaartje, Makanyanga, Jesica, Barnova, Ivana, Saravanapavan, Hajeena, Parisi, Ioanna, Di Caro, Simona, Vega, Roser, Rahman, Farooq, McCartney, Sara, Bloom, Stuart L, van den Brink, Gijs R, Löwenberg, Mark, Ponsioen, Cyriel Y, Buskens, Christianne J, Tanis, Pieter J, de Buck van Overstraeten, Anthony, DʼHoore, Andre, Bemelman, Willem A, DʼHaens, Geert R

“…Restorative proctocolectomy with ileal pouch-anal anastomosis is the operation of choice for patients with treatment-refractory ulcerative colitis. However,…”
Get full text

Performance of Common Disease Activity Markers as a Reflection of Inflammatory Burden in Ulcerative Colitis by Brandse, Johannan F, Bennink, Roel J, van Eeden, Susanne, Löwenberg, Mark, van den Brink, Gijs R, DʼHaens, Geert R

“…The inflammatory burden influences therapeutic decisions in patients with ulcerative colitis (UC). We aimed to study which commonly used markers of disease…”
Get full text

Explaining Interpatient Variability in Adalimumab Pharmacokinetics in Patients With Crohn's Disease by Berends, Sophie E, Strik, Anne S, Van Selm, Juliet C, Löwenberg, Mark, Ponsioen, Cyriel Y, DʼHaens, Geert R, Mathôt, Ron A

“…A significant proportion of patients with Crohn's disease (CD) require dose escalation or fail adalimumab (ADL) therapy over time. ADL, a monoclonal antibody…”
Get full text

Fecal Calprotectin Correlates With Histological Disease Activity in Ulcerative Colitis: A Post-Hoc Analysis of the MOMENTUM Trial: 719 by Stevens, Toer W., Gecse, Krisztina, Barrett, Karen, Turner, Jerrold R., de Hertogh, Gert, Rubin, David T., DʼHaens, Geert R.

“…Introduction: Evidence suggests an association between histological inflammation and clinical relapse in ulcerative colitis (UC). Fecal calprotectin (FC)…”
Get full text

Assessment of histologic disease activity in Crohn's disease: a systematic review by Mojtahed, Amirkaveh, Khanna, Reena, Sandborn, William J, D'Haens, Geert R, Feagan, Brian G, Shackelton, Lisa M, Baker, Kenneth A, Dubcenco, Elena, Valasek, Mark A, Geboes, Karel, Levesque, Barrett G

“…Crohn's disease (CD) is an idiopathic, chronic, transmural inflammatory disorder of the gastrointestinal tract. Because mucosal involvement is near-universal,…”
Get full text

Long-Term Safety, Efficacy and Pharmacokinetics of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1) Monoclonal Antibody SHP647 in Crohnʼs Disease: The OPERA II Study: 606 by DʼHaens, Geert R., Reinisch, Walter, Lee, Scott D., Tarabar, Dino, Louis, Edouard, Klopocka, Maria, Klaus, Jochen, Schreiber, Stefan, Park, Dong Il, Hébuterne, Xavier, Cataldi, Fabio, Martin, Steven W., Nayak, Satyaprakash, Banerjee, Anindita, Gorelick, Kenneth J., Sandborn, William J.

“…Introduction: The endothelial adhesion protein mucosal addressin cell adhesion molecule-1 (MAdCAM-1) is a promising novel drug target. The fully human IgG2…”
Get full text

Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease by D'Haens, Geert R., Fedorak, Richard, Lémann, Marc, Feagan, Brian G., Kamm, Michael A., Cosnes, Jacques, Rutgeerts, Paul J., Marteau, Philippe, Travis, Simon, Schölmerich, Jürgen, Hanauer, Steven, Sandborn, William J.

“…The management of Crohn's disease is rapidly changing. The advent of potent immunomodulatory and biologic therapies has led to more demanding endpoints for…”
Get full text

Diagnostic Accuracy of Fecal Calprotectin Concentration in Evaluating Therapeutic Outcomes of Patients With Ulcerative Colitis by Stevens, Toer W., Gecse, Krisztina, Turner, Jerrold R., de Hertogh, Gert, Rubin, David T., D’Haens, Geert R.

“…Histologic features of inflammation (histologic inflammation) are associated with clinical relapse in patients with ulcerative colitis (UC). Concentration of…”
Get full text

Peripheral blood methylation profiling of female Crohn's disease patients by Li Yim, Andrew Y F, Duijvis, Nicolette W, Zhao, Jing, de Jonge, Wouter J, D'Haens, Geert R A M, Mannens, Marcel M A M, Mul, Adri N P M, Te Velde, Anje A, Henneman, Peter

“…Crohn's disease (CD) is a chronic inflammatory disorder belonging to the inflammatory bowel diseases (IBD). CD affects distinct parts of the gastrointestinal…”
Get full text